Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.
about
The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansPreliminary morphological and biochemical changes in rat liver following postnatal exposure to sodium arseniteAntiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs studyAntiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients.Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markersLiver disease, HIV and aging.Risk factors for fatty liver in the Multicenter AIDS Cohort Study.Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopyChronic liver disease in the Hispanic population of the United States.Liver disease in the HIV-infected individual.Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.Hepatitis E and pregnancy: understanding the pathogenesis.Coinfection with HIV-1 and HCV--a one-two punch.Human immunodeficiency virus infection and the liverDysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article.Management of hepatic complications in HIV-infected persons.Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factorsHepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons.Nonalcoholic fatty liver disease among HIV-infected persons.Hepatitis C Virus and HIV Type 1 Co-Infection.The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?Lipids and HCV.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction.Liver involvement in human immunodeficiency virus infection.Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.Etiology, clinical profile, and outcome of liver disease in pregnancy with predictors of maternal mortality: A prospective study from Western India.Non-viral liver disease burden in HIV-monoinfected individuals: a longitudinal observational retrospective cohort study.Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.Reduced glutathione in hepatitis E infection and pregnancy outcome.Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
P2860
Q26781379-3140C720-9FD8-45D7-B36A-5B268B45C4ECQ28392418-43C180E6-FD96-4B0F-A6FC-ED4991F158F4Q30574483-662B92BF-8FCC-476A-B735-0DF185944190Q31050092-34C589E9-CC9E-45EC-B71B-5B146A2D974FQ31054551-29D8B00A-5B02-4B29-B2A9-62B019876014Q33621724-14B3500E-9A85-42AF-9B9F-576F794F5A3CQ33810577-C5FEFE4A-0A3F-4383-95D1-B4B47D129659Q34049896-22EB6B56-B239-4C66-928B-22E986100606Q34148144-135B272A-3997-4F66-A677-F00B55E18F97Q34284875-4179AAEC-081E-4CD4-A629-74FBF94C08DCQ34380326-3834BCED-94D5-482D-92B5-65E2D0D30013Q34704820-39098353-64C4-46AD-BBB5-DEAC6CFA22ABQ34777095-11020651-0A19-4E78-BCC9-A4BB675F1B06Q34801927-96FF35C8-8E18-4E06-8616-FB591E086C83Q35137038-D2FBC945-4014-4F54-8FAC-5CD7749F20D2Q35875848-7947C862-BD2F-4333-A71F-BA0D46FB1F64Q36158019-F62DF972-5407-457F-A5ED-D7F743191727Q36532400-DAD58DFB-6701-46EC-8074-65CAEFBE3543Q36672577-5736D0EB-85DD-4F08-BD64-6D929581C9DAQ36820091-25BE1BF7-9EE7-4F14-B238-E3B1C4AF6205Q37151303-E40A42AC-3C2F-4692-9A57-0818233AA83DQ37152712-E1300843-1F72-441A-8426-27EFA8FD8043Q37238258-43921EBC-53CF-4691-9E12-69DBD0E73A09Q37434578-7A622643-65D1-4552-AF04-00DCCC47039CQ37481988-E3B5EF10-58D4-4D43-A12F-E677CF6C4A41Q37518294-88D5A5FB-DB20-4C10-A7A1-04E5DC09B3F7Q37644125-4D91FE9F-F57D-489E-BCFF-CE6CD0152C63Q38056643-AA3CCDD8-F24E-40D9-BFD2-2CC54B6B5CB1Q38325427-EEF35281-4B02-482D-A3BB-0B76310E4BD1Q38614025-DC473A64-459E-4463-A89E-5A7E91208068Q38805500-1009D256-7480-429A-9CD3-6584A4C3D3EBQ38852184-926880B4-1088-4B98-BB6C-F865BA604E53Q38915274-0767420C-1057-4A15-979C-D00AC8AD9F97Q39160282-77F7F45E-4217-4500-933D-513B613EAE23Q39476172-21B67852-5289-4BD5-B225-6064C675A29DQ39708861-16FFDEF5-4390-478E-BA2A-A4DCE0D571FAQ39877513-33E6A526-4C85-4D8E-812F-7B3561743FA4Q40360505-1C273128-43D4-4127-A283-9B404A211E86Q40716233-2FF443B6-FC9F-4C22-B9DB-1155BCA57808Q41923080-358B2F1E-CDC9-432C-B0E7-B0577D55791C
P2860
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@ast
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@en
type
label
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@ast
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@en
prefLabel
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@ast
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@en
P2093
P2860
P356
P1476
Hepatic steatosis is associate ...... in HIV-seropositive patients.
@en
P2093
Anne-Marie Fiorino
Barbara H McGovern
Beth Schwartzapfel
Emily Rindler
Fiona Graeme-Cook
Jeremy S Ditelberg
Katerina A Christopoulos
Lynn E Taylor
M Tauheed Zaman
Patricia L Hibberd
P2860
P304
P356
10.1086/505495
P407
P577
2006-06-22T00:00:00Z